Latest News

8th January, 2016

OncoImmunity collaborates with a cancer therapeutic vaccine company

OncoImmunity enters into a collaboration with a vaccine company to identify immunogenic neoantigen signatures in a vaccine clinical trial, in combination checkpoint inhibitor therapy.

More Recent News

8th Apr 2022
CEPI partners with Japan’s NEC Group to develop artificial intelligence-designed broadly protective betacoronavirus vaccine
8th Mar 2022
NEC OncoImmunity Acquires VAXIMM’s Neoantigen Vaccine Development Assets
17th Feb 2022
NEC OncoImmunity publishes a unique HLA typing technology that discovers new HLA alleles, and tumor specific HLA alleles
Legal
Company
Our Locations
  • Oslo Cancer Cluster
  • Oslo Cancer Cluster Incubator
© NEC OncoImmunity AS 2022.
Please enable your browser to accept cookies and refresh this page to enjoy the best experience from this website and to dismiss this message.
In order to provide you with the best online experience this website uses cookies. By using our website, you agree to our use of cookies.OK